Merck says FDA reviewing its ragweed allergy therapy

by The Associated Press

Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, itching and other symptoms temporarily.

Merck's latest application is for an allergy immunotherapy tablet for ragweed allergies that dissolves under the tongue. Patients in studies of the tablet took it daily for a year.

It could become an alternative to months of uncomfortable allergy shots. Both methods gradually desensitize the immune system to the substance triggering the allergic reaction.

In March, the Whitehouse Station, N.J., company said the was reviewing its application for an immunotherapy tablet for grass pollen allergies.

expects FDA rulings on both still-unnamed treatments in 2014's first half.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Merck: FDA reviewing tablet to eliminate allergy

Mar 27, 2013

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that gradually reduces allergy symptoms over time, rather than just temporarily relieving ...

Researchers evaluating food allergy treatment

Apr 17, 2008

Researchers at National Jewish Medical and Research Center are conducting trials to evaluate a method to prevent allergic reactions to food. They are feeding peanut- and egg-allergic people increasing doses of an investigational ...

Life saving treatment for fire ant allergy under used

Mar 04, 2013

Two million Americans are allergic to insect stings, an allergy which sends more than 500,000 people to the emergency room annually. Yet, according to a study published today in the March issue of Annals of Allergy, Asthma & ...

Recommended for you

EU regulator: Morning-after pill OK for all women

2 hours ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

6 hours ago

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

Zydelig approved for three types of blood cancer

7 hours ago

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) ...

Journal raises concern about blood-thinning drug

20 hours ago

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

User comments